SARS-CoV-2 public health investigation in an aged care facility and challenges with serological screening in low pre-test probability settings

Authors

  • Nicolas R Smoll Central Queensland Public Health Unit, Central Queensland Hospital and Health Service, Rockhampton, Queensland, Australia
  • Carmel Taylor Forensic and Scientific Services, Queensland Health, Brisbane, Queensland, Australia
  • Ross Martin Pathology Queensland, Rockhampton, Queensland, Australia
  • Sarah Wheatley Forensic and Scientific Services, Queensland Health, Brisbane, Queensland, Australia
  • Peter Moore Forensic and Scientific Services, Queensland Health, Brisbane, Queensland, Australia
  • Mitchell Finger Forensic and Scientific Services, Queensland Health, Brisbane, Queensland, Australia
  • Frederick Moore Forensic and Scientific Services, Queensland Health, Brisbane, Queensland, Australia
  • Sanmarié Schlebusch Forensic and Scientific Services, Queensland Health, Brisbane, Queensland, Australia; Pathology Queensland Central Laboratory, Brisbane, Queensland, Australia
  • Gulam Khandaker Central Queensland Public Health Unit, Central Queensland Hospital and Health Service, Rockhampton, Queensland, Australia

DOI:

https://doi.org/10.33321/cdi.2021.45.42

Keywords:

SARS-CoV-2, serosurvey, aged care facility

Abstract

Findings from a study in Queensland support the use of the SARS-CoV-2 MIA followed by neutralisation testing confirmation for screening in large-scale seroprevalence studies in low-pretest probability environments such as aged care facilities.

Downloads

Download data is not yet available.

References

Gidding HF, Machalek DA, Hendry AJ, Quinn HE, Vette K, Beard FH et al. Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave of 2020. Med J Aust. 2021;214(4):179–85. doi: https://doi.org/10.5694/mja2.50940.

Bajema KL, Wiegand RE, Cuffe K, Patel SV, Iachan R, Lim T et al. Estimated SARS-CoV-2 seroprevalence in the US as of September 2020. JAMA Intern Med. 2020;e207976. doi: https://doi.org/10.1001/jamainternmed.2020.7976.

Public Health Laboratory Network (PHLN). Public Health Laboratory Network Guidance for serological testing in COVID-19, version 1.3. Canberra: Australian Government Department of Health; 3 September 2020. Available from: https://www.health.gov.au/sites/default/files/documents/2020/09/phln-guidance-for-serological-testing-in-covid-19-phln-guidance-on-serological-testing-in-covid-19.pdf.

State Health Emergency Coordination Centre (SHECC). Situation Report No. 159. Brisbane: Queensland Government, Queensland Health, SHECC; October 2021.

Downloads

Published

16/08/21

How to Cite

Smoll, Nicolas R, Carmel Taylor, Ross Martin, Sarah Wheatley, Peter Moore, Mitchell Finger, Frederick Moore, Sanmarié Schlebusch, and Gulam Khandaker. 2021. “SARS-CoV-2 Public Health Investigation in an Aged Care Facility and Challenges With Serological Screening in Low Pre-Test Probability Settings”. Communicable Diseases Intelligence 45 (August). https://doi.org/10.33321/cdi.2021.45.42.

Issue

Vol. 45 (2021)

Section

Letter to the Editor

Categories

License

Copyright (c) 2021 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 3 > >>